Antidepressant use and lifetime history of mental disorders in a community sample: Results from the Baltimore Epidemiologic Catchment Area study

Journal of Clinical Psychiatry

Volumn 76, Issue 1, 2015, Pages 40-44

  Takayanagi, Yoichiro ^a   Spira, Adam P ^a,b   Bienvenu, O Joseph ^b   Hock, Rebecca S ^a   Carras, Michelle C ^a   Eaton, William W ^a   Mojtabai, Ramin ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BACKACHE; BLADDER DISEASE; CAUCASIAN; COMMUNITY SAMPLE; CONTROLLED STUDY; DRUG USE; DSM-III; DSM-III-R; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; GENDER; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERTENSION; INTERVIEW; LIFESPAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHYSICAL DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SOCIAL PHOBIA; ANXIETY DISORDERS; DEPRESSIVE DISORDER; LONGITUDINAL STUDY; MENTAL DISORDERS; MIDDLE AGED; UNITED STATES;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BALTIMORE; DEPRESSIVE DISORDER; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MIDDLE AGED; PREVALENCE;

EID: 84925358962     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08824     Document Type: Article

References (34)

1. Mojtabai R. Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychother Psychosom. 2008;77(2):83-92.
2. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66(8):848-856.
3. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Br J Psychiatry. 2012;200(5):393-398.
4. Mojtabai R, Olfson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication. J Clin Psychiatry. 2008;69(7):1064-1074.
5. Pagura J, Katz LY, Mojtabai R, et al. Antidepressant use in the absence of common mental disorders in the general population. J Clin Psychiatry. 2011;72(4):494-501.
6. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood). 2011;30(8):1434-1442.
7. Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs. 2006;20(8):623-632.
8. Demyttenaere K, Bonnewyn A, Bruffaerts R, et al. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD). J Affect Disord. 2008;110(1-2):84-93.
9. Zhang Y, Chow V, Vitry AI, et al. Antidepressant use and depressive symptomatology among older people from the Australian Longitudinal Study of Ageing. Int Psychogeriatr. 2010;22(3):437-444.
10. Parabiaghi A, Franchi C, Tettamanti M, et al. Antidepressants utilization among elderly in Lombardy from 2000 to 2007: dispensing trends and appropriateness. Eur J Clin Pharmacol. 2011;67(10):1077-1083.
11. Carrasco-Garrido P, López de Andrés A, Hernández Barrera V, et al. National trends (2003-2009) and factors related to psychotropic medication use in community-dwelling elderly population. Int Psychogeriatr. 2013;25(2):328-338.
12. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Washington, DC: American Psychiatric Association; 2010.
13. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.
14. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III: tolerability, safety and pharmacoeconomics. J Psychopharmacol. 1998;12(suppl B):S55-S87.
15. Moffitt TE, Caspi A, Taylor A, et al. How common are common mental disorders? evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. Psychol Med. 2010;40(6):899-909.
16. Eaton WW, Kalaydjian A, Scharfstein DO, et al. Prevalence and incidence of depressive disorder: the Baltimore ECA follow-up, 1981-2004. Acta Psychiatr Scand. 2007;116(3):182-188.
17. Robins LN, Helzer JE, Croughan J, et al. National institute of mental health diagnostic interview schedule. its history, characteristics, and validity. Arch Gen Psychiatry. 1981;38(4):381-389.
18. Robins LN, Helzer JE, Croughan J, et al. NIMH Diagnostic Interview Schedule: Version III. St Louis, MO: Washington University School of Medicine; 1981.
19. Robins L. NIMH Diagnostic Interview Schedule: Version III Revised (DIS-III-R). St Louis, MO: Washington University School of Medicine; 1989.
20. Conti R, Busch AB, Cutler DM. Overuse of antidepressants in a nationally representative adult patient population in 2005. Psychiatr Serv. 2011;62(7):720-726.
21. Eguale T, Buckeridge DL, Winslade NE, et al. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med. 2012;172(10):781-788.
22. Mark TL, Levit KR, Buck JA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 2009;60(9):1167.
23. Mark TL. For what diagnoses are psychotropic medications being prescribed? a nationally representative survey of physicians. CNS Drugs. 2010;24(4):319-326.
24. Samples H, Mojtabai R. Antidepressant use in the European union: perceived indications and patterns. Psychiatr Serv. 2013;64(3):208.
25. Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72(4):509-514.
26. von Wolff A, Hölzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord. 2013;144(1-2):7-15.
27. Bossini L, Casolaro I, Koukouna D, et al. Off-label uses of trazodone: a review. Expert Opin Pharmacother. 2012;13(12):1707-1717.
28. Barbui C, Cipriani A, Patel V, et al. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry. 2011;198(1):11-16, 1.
29. Hegerl U, Schönknecht P, Mergl R. Are antidepressants useful in the treatment of minor depression: a critical update of the current literature. Curr Opin Psychiatry.
30. Mojtabai R. Unmet need for treatment of major depression in the United States. Psychiatr Serv. 2009;60(3):297-305.
31. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.
32. Mojtabai R. The public health impact of antidepressants: an instrumental variable analysis. J Affect Disord. 2011;134(1-3):188-197.
33. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374(9690):609-619.
34. Mojtabai R. Does depression screening have an effect on the diagnosis and treatment of mood disorders in general medical settings? an instrumental variable analysis of the national ambulatory medical care survey. Med Care Res Rev. 2011;68(4):462-489.